Patents by Inventor Agnes M. Rimando
Agnes M. Rimando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190059368Abstract: Analogs of stilbene, and in particular, 3,5-dimethoxystilbene, are disclosed. Also disclosed are various uses for the different compounds described. The uses of the disclosed 3,5-dimethoxystilbene analogs include treatment as a pesticide, nematicide, fungicide, bactericide, and antimicrobial agent. Many of the analogs are novel, and procedures for synthesis are also provided.Type: ApplicationFiled: August 7, 2018Publication date: February 28, 2019Inventors: AGNES M. RIMANDO, JIAN-QUAN WENG
-
Patent number: 9439875Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.Type: GrantFiled: May 11, 2011Date of Patent: September 13, 2016Assignees: The United States of America, as represented by The Secretary of Agriculture, University of MississippiInventors: Agnes M. Rimando, Abir El-Alfy, Md Al Rahim
-
Publication number: 20160067192Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.Type: ApplicationFiled: May 11, 2011Publication date: March 10, 2016Inventors: Agnes M. Rimando, Abir El-Alfy, Md Al Rahim
-
Patent number: 9248145Abstract: Sorghum is considered an allelopathic crop species and sorgoleone likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Quantitative real-time RT-PCR analysis of PKS-like sequences mined from isolated root hairs revealed that two sequences, designated ARS1 and ARS2, were preferentially expressed. Recombinant enzyme studies demonstrated that both sequences encode ARS enzymes capable of accepting a variety of fatty acyl-CoA starter units. RNA interference (RNAi) experiments directed against ARS1 and ARS2 resulted in the generation of multiple independent transformant events exhibiting dramatically reduced sorgoleone levels.Type: GrantFiled: March 10, 2010Date of Patent: February 2, 2016Assignee: The United States of America, as represented by The Secretary of AgricultureInventors: Scott R. Baerson, Zhiqiang Pan, Agnes M. Rimando, Franck E. Dayan, Daniel Cook
-
Patent number: 9028887Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.Type: GrantFiled: May 22, 2014Date of Patent: May 12, 2015Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
-
Publication number: 20140256827Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.Type: ApplicationFiled: May 22, 2014Publication date: September 11, 2014Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
-
Patent number: 8809400Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.Type: GrantFiled: August 8, 2011Date of Patent: August 19, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
-
Patent number: 8426369Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.Type: GrantFiled: December 7, 2007Date of Patent: April 23, 2013Assignee: Rutgers, The State University of New JerseyInventors: Agnes M. Rimando, Nanjoo Suh, Cassia Suemi Mizuno, Subhashini Reddy
-
Patent number: 8383890Abstract: This invention relates to the fatty acid desaturase genes, designated SbDES2 and SbDES3, cloned from an expressed sequence tag (EST) database prepared from isolated root hairs from sorghum. Heterologous expression of the cDNAs in S. cerevisiae revealed that recombinant SbDES2 converted palmitoleic acid (16:1?9) to hexadecadienoic acid (16:2?9, 12), and that recombinant SbDES3 was capable of converting hexadecadienoic acid into hexadecatrienoic acid (16:3?9, 12, 15). Desaturase enzymes capable of performing desaturation reactions producing a terminal double bond have not previously been characterized in a plant system.Type: GrantFiled: December 15, 2006Date of Patent: February 26, 2013Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Zhiqiang Pan, Agnes M. Rimando, Scott R. Baerson
-
Patent number: 8252845Abstract: Resveratrol has been reported to have hypolipidemic properties. We investigated whether resveratrol and its analogs: pterostilbene, piceatannol and resveratrol trimethyl ether, would activate the peroxisome proliferator-activated receptor alpha (PPAR?) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells transfected with a luciferase gene reporter construct. Pterostilbene demonstrated the highest induction of PPAR?; the maximal response to pterostilbene was similar to that obtained with the hypolipidemic drug, ciprofibrate.Type: GrantFiled: February 1, 2012Date of Patent: August 28, 2012Assignees: The United States of America, as represented by the Secretary of Agriculture, The University of MississippiInventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
-
Publication number: 20120178704Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.Type: ApplicationFiled: December 7, 2007Publication date: July 12, 2012Inventors: Agnes M. Rimando, Nanjoo Suh, Cassia Mizuno, Bandaru s. Reddy, Sada L. Reddy
-
Patent number: 8133917Abstract: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPAR?) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPAR? demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPAR? agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.Type: GrantFiled: October 25, 2010Date of Patent: March 13, 2012Assignees: The United States of America as represented by the Secretary of Agriculture, The University of MississippiInventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
-
Publication number: 20120035272Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.Type: ApplicationFiled: August 8, 2011Publication date: February 9, 2012Applicant: The United States of America as represented by the Secretary of AgricultureInventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
-
Publication number: 20110225676Abstract: Sorghum is considered to be an allelopathic crop species, producing phytotoxins such as the lipid benzoquinone sorgoleone (2-hydroxy-5-methoxy-3-[(Z,Z)-8?,11?,14?-pentadecatriene]-p-benzoquinone) which likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone have suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Current evidence suggests that sorgoleone biosynthesis occurs exclusively in root hair cells, involving the synthesis of a 5-pentadecatrienyl resorcinol intermediate derived from an unusual 16:3 fatty acyl-CoA starter unit.Type: ApplicationFiled: March 10, 2010Publication date: September 15, 2011Inventors: Scott R. Baerson, Zhiqiang Pan, Agnes M. Rimando, Franck E. Dayan, Daniel Cook
-
Publication number: 20110060060Abstract: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPAR?) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPAR? demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPAR? agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.Type: ApplicationFiled: October 25, 2010Publication date: March 10, 2011Inventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
-
Patent number: 7732666Abstract: This invention relates to an O-methyltransferase gene cloned from sorghum, the sorghum O-methyltransferase-3 gene, SbOMT3. Quantitative real-time RT-PCR and recombinant enzyme studies with putative O-methyltransferase sequences obtained from an EST data set from sorghum have led to the identification of the novel root hair-specific O-methyltransferase designated SbOMT3. Transgenic plants which express SbOMT3 can convert resveratrol into pterostilbene in planta. SbOMT3 is also involved in the biosynthesis of sorgoleone.Type: GrantFiled: September 1, 2006Date of Patent: June 8, 2010Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Scott R. Baerson, Agnes M. Rimando, Franck E. Dayan, Zhiqiang Pan, James J. Polashock
-
Publication number: 20090069444Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.Type: ApplicationFiled: June 10, 2008Publication date: March 12, 2009Applicant: The United States of America, as represented by th e Secretary of AgricultureInventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale